Abstracts tagged "Spondyloarthropathies"

Abstract Number: 0854 • ACR Convergence 2022
Outcome of Uveitis in Juvenile Idiopathic Arthritis and Spondyloarthritis Patients – a 5-year Follow up Study
Filipe Pinheiro¹, Mariana Leuzinger-Dias², Bruno Fernandes³, Diogo Fonseca⁴, Joana Vilaça⁵, Luís Figueira⁶ and Iva Brito⁷, ¹Rheumatology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, ²Ophtalmology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, ³Rheumatology Deparment, Centro Hospitalar e Universitário de São João, Porto, Portugal, ⁴Rheumatology Department, Centro Hospitalar de Vila Nova de Gaia / Espinho, Vila Nova de Gaia, Portugal, ⁵Paediatrics Department, Hospital de Braga, Braga, Portugal, ⁶Ophthalmology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, ⁷Pediatric and Young Adult Rheumatology Unit, Centro Hospitalar Universitário de São João, Porto, Portugal
Background/Purpose: Uveitis is a frequent complication of juvenile idiopathic arthritis (JIA) and juvenile spondyloarthritis (jSpA), and diagnosis is often challenging. The importance of uveitis relates…
Abstract Number: 1162 • ACR Convergence 2022
Improvement of Gut Microbiota Dysbiosis in Patients with Axial Spondyloarthritis After One Year of Biological Treatment
valeria Rios-Rodriguez¹, Morgan Essex², Judith Rademacher³, Murat Torgutalp⁴, Fabian Proft⁵, Ulrike Löber², Lajos Marko², Sofia Forslund² and Denis Poddubnyy⁵, ¹Charité-Universitätsmedizin Berlin, Berlin, Germany, ²Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association, Berlin, Germany, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité - Universitätsmedizin, Berlin, Berlin, Germany, ⁵Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: There is little evidence about the effect of biological disease-modifying antirheumatic drugs (bDMARD) on gut dysbiosis in patients with axial SpA. Here we investigated…
Abstract Number: 2111 • ACR Convergence 2022
Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
Dafna Gladman¹, Michael Starr², Roberto Ranza³, Ana-Maria Bravo Perdomo⁴, Marcie Strauss⁵, May Shawi⁶, Chenglong Han⁷, Emmanouil Rampakakis⁸, Andrew Ostor⁹ and Philip J Mease¹⁰, ¹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ²Montreal General Hospital, Montréal, QC, Canada, ³Serviço de Reumatología, Universidade Federal de Uberlândia, Uberlândia, Brazil, ⁴Immunology Medical Affairs, Janssen Latin America, Columbia, Colombia, ⁵Medasource, Indianapolis, IN, ⁶Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁷Immunology, Janssen Research & Development, LLC, Spring House, PA, ⁸McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁹Cabrini Medical Centre, Monash University & Emeritus Research, Melbourne, Australia, ¹⁰Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: The IL-23p19-subunit inhibitor guselkumab (GUS) demonstrated clinically meaningful improvements in fatigue through one year of treatment1 independent of its effects on ACR20 and MDA…
Abstract Number: 0865 • ACR Convergence 2022
Opioid Use in Youth with Inflammatory Bowel Disease (IBD)-related Arthritis
Atiye Bilgic Dagci¹, Joyce Chang², Rui Xiao³, Andrew Grossman⁴ and Pamela Weiss⁵, ¹Children's Hospital of Philadelphia, Bala Cynwyd, PA, ²Boston Children's Hospital, Boston, MA, ³University of Pennsylvania, Philadelphia, PA, ⁴Children's Hospital of Philadelphia, Philadelphia, ⁵Children's Hospital of Philadelphia, Glen Mills, PA
Background/Purpose: Opioid use is common among youth with IBD and associated with increased health care utilization and opioid dependence. Arthritis affects up to 20% of…
Abstract Number: 1164 • ACR Convergence 2022
Expanded CD8+ T Cell Clones from HLA-B*27-positive Patients with Spondyloarthritis Show Signs of Antigen-experience
Judith Rademacher¹, Katharina Deschler², Sonja Lacher², Alina Huth², Markus Utzt², Stefan Krebs², Helmut Blum², Eduardo Beltrán², Klaus Dornmair² and Denis Poddubnyy³, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Laboratory for Functional Genome Analysis (LAFUGA), Gene Center of the LMU Munich, Munich, Germany, ³Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Spondyloarthritis (SpA) is strongly associated with HLA-B27. The arthritogenic antigen hypothesis assumes the existence of specific peptides presented by risk-conferring HLA-B27 alleles to antigen-specific…
Abstract Number: 2112 • ACR Convergence 2022
Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Christopher Ritchlin¹, Philip J Mease², Wolf-Henning Boehncke³, John Tesser⁴, Soumya Chakravarty⁵, Emmanouil Rampakakis⁶, May Shawi⁷, Elena Schiopu⁸, Joseph Merola⁹, Iain B McInnes¹⁰ and Atul Deodhar¹¹, ¹Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ²Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ³Deptartment of Dermatology, Geneva University Hospitals, University of Geneva, Geneva, Switzerland, ⁴Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁵Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁶McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸Michigan Medicine Rheumatology Clinic – Taubman Center, Ann Arbor, MI, ⁹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹⁰Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ¹¹Oregon Health & Science University, Portland, OR, USA, Portland, OR
Background/Purpose: Guselkumab (GUS) is associated with robust and sustained improvement in PsA signs and symptoms in subgroups of patients (pts) pooled from the phase 3…
Abstract Number: 0868 • ACR Convergence 2022
Spondyloarthritis and Neonatal Factors Affecting the Gut Microbiome
Joy Um¹, Douglas Einstadter², Myung-Yong Um³ and Maria Antonelli¹, ¹Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ²Center for Health Care Research and Policy, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ³Department of Social Welfare, Sungkyunkwan University, Seoul, Republic of Korea
Background/Purpose: Spondyloarthritis (SpA) consists of clinically and genetically related but phenotypically distinct disorders, including ankylosing spondylitis, enteropathic arthritis, psoriatic arthritis, reactive arthritis, and enthesitis-related arthritis…
Abstract Number: 1234 • ACR Convergence 2022
Characterizing Imaging Phenotypes in PsA: The Effect of Age and Sex
Lihi Eder¹ and Kangping Cui², ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada
Background/Purpose: Musculoskeletal ultrasound (MSK-US) provides valuable information on disease phenotype in psoriatic arthritis (PsA). While age and sex are important determinants of health, limited information…
Abstract Number: 2114 • ACR Convergence 2022
Early Clinical Improvement as Predictor of Long-term Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Guselkumab: Post Hoc Analysis Through 2 Years of a Phase 3 Study
Iain B McInnes¹, Enrique R Soriano², Lai-shan Tam³, Natalie Shiff⁴, May Shawi⁵, Emmanouil Rampakakis⁶ and Jeffrey Curtis⁷, ¹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ²Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³The Chinese University of Hong Kong, Hong Kong, China, ⁴Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA, ⁵Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁶McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁷University of Alabama at Birmingham, Division of Immunology and Rheumatology, Birmingham, AL
Background/Purpose: Patients (pts) with PsA experience lower quality of life than both the general population and pts with psoriasis alone1,2. Recent PsA treatment recommendations highlight…
Abstract Number: 0954 • ACR Convergence 2022
What Drives the BASDAI in Pregnant Patients with Axial Spondyloarthritis? A Pooled Analysis of Four European Pregnancy Registries
Yvette Meissner¹, Nathalie Costedoat-Chalumeau², Rebecca Fischer-Betz³, Frauke Foerger⁴, Anna Molto⁵, Marianne Wallenius⁶ and Anja Strangfeld¹, ¹Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ²Inserm DR Paris 5, Paris, France, ³Uniklinik Duesseldorf, Duesseldorf, Germany, ⁴Inselspital Bern, Bern, Switzerland, ⁵Rheumatology Department, Cochin Hospital, APHP, Paris, France, ⁶St. Olav University Hospital, Trondheim, Norway
Background/Purpose: The patient reported Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) includes the six components fatigue, neck, back or hip pain, pain or swelling in…
Abstract Number: 1250 • ACR Convergence 2022
Physiologic Adaptive Change of the Patellar and Achilles Tendons: Sensitivity to Change Detected by Computer Analysis of Sequential Static Images
CARLOS ANTONIO GUILLEN ASTETE, Africa Andreu Suarez and Marina Tortosa Cabanas, Ramon y Cajal University Hospital, Madrid, Spain
Background/Purpose: Ultrasound studies stratify the results of the evaluations in ordinal degrees of intensity of findings dependent on the evaluator's opinion. Computer analysis of static…
Abstract Number: 2115 • ACR Convergence 2022
Early Skin and Early Enthesitis Responses in Psoriatic Arthritis Patients Treated with Guselkumab Associate with Long-term Response: Post Hoc Analysis Through 2 Years of a Phase 3 Study
Laura Coates¹, Julio Ramírez², Dennis McGonagle³, Sibel Aydin⁴, Miriam Zimmermann⁵, Francois Nantel⁶, May Shawi⁷, Emmanouil Rampakakis⁸, Peter Nash⁹ and Philip J Mease¹⁰, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ²Arthritis Unit, Rheumatology Department, Hospital Clinic, Barcelona, Spain, ³University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁴University of Ottawa, Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁵Immunology, Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁶Nantel MedSci Consult, Montréal, QC, Canada, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁹School of Medicine, Griffith University, Sunshine Coast, Australia, ¹⁰Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Guselkumab (GUS), an IL-23p19 inhibitor, has demonstrated efficacy in PsA across key Group for Research and Assessment of Psoriasis (PsO) and Psoriatic Arthritis (GRAPPA)-recommended…
Abstract Number: 0069 • ACR Convergence 2022
Capturing Clinical Reasoning in Real Time Reveals Low Rate of Serious Adverse Reactions Requiring B/tsDMARD Discontinuation in Inflammatory Joint Disease: An Analysis of the OPAL Real-World Dataset
Geoffrey Littlejohn¹, Tegan Smith², Sabina Ciciriello³, Peter Youssef⁴, Claire Deakin⁵, Nithila Anbumurali⁶ and Catherine OSullivan⁶, ¹OPAL Rheumatology Ltd, Melbourne, Australia, ²OPAL Rheumatology Ltd, Geelong, Australia, ³Melbourne Health, Melbourne, Australia, ⁴University of Sydney, Sydney, Australia, ⁵OPAL Rheumatology Ltd, Mosman, Australia, ⁶OPAL Rheumatology Ltd, Sydney, Australia
Background/Purpose: Routine management of inflammatory joint disease requires clinicians to consider an abundance of factors unique to each patient when deciding on the most appropriate…
Abstract Number: 1004 • ACR Convergence 2022
SPARCC, MASES, LEI and MEI Indexes Capture Different Patients with Enthesitis in Axial Spondyloarthritis, Peripheral Spondyloartrhitis and Psoriatic Arthritis
Raquel Granados¹, lourdes Ladehesa-Pineda², Maria Angeles Puche Larrubia³, Maxime Dougados⁴, Eduardo Collantes⁵ and Clementina Lopez-Medina⁶, ¹Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, ²Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, ³Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Granada, Spain, ⁴Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, ⁵IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ⁶Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain
Background/Purpose: Spondyloarthritis, (axial (axSpA), peripheral (pSpA)) and psoriatic arthritis (PsA)) share enthesitis as a hallmark clinical feature. Reliable clinical instruments have been developed to assess…
Abstract Number: 1253 • ACR Convergence 2022
Gray Intensity Ratio Indices as a Method of Discrimination Between Changes Induced by Sport and by Spondyloarthritis in Load-bearing Entheses
Marina Tortosa Cabanas, CARLOS ANTONIO GUILLEN ASTETE and Africa Andreu Suarez, Ramon y Cajal University Hospital, Madrid, Spain
Background/Purpose: Computer analysis of radiological images has been recently introduced in the study of patients with musculoskeletal pathologies. Our research group has shown that this…

« Previous Page
1
…
8
9
10
11
12
…
15
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].